H.C. Wainwright analyst Andrew Fein says that with the manufacturing update in February, as well as Julie O'Neil's engagement with the process, he does not foresee any other roadblocks as DBV Technologies moves towards the resubmission of its Biologics License Application in Q3. DBV should "now have the right stewardship to remedy the issues at hand," Fein tells investors in a research note. He thinks a "smooth and successful" execution of the BLA resubmission could reinvigorate investors' confidence in the management team, remove the regulatory overhang, and be a "meaningful catalyst" for the shares. The analyst reiterates a Buy rating on DBV Technologies with a $25 price target.